» Articles » PMID: 33791799

Selective Serotonin Reuptake Inhibitor Citalopram Ameliorates Cognitive Decline and Protects Against Amyloid Beta-induced Mitochondrial Dynamics, Biogenesis, Autophagy, Mitophagy and Synaptic Toxicities in a Mouse Model of Alzheimer's Disease

Overview
Journal Hum Mol Genet
Date 2021 Apr 1
PMID 33791799
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

In the current study, we investigated the protective role of citalopram against cognitive decline, impaired mitochondrial dynamics, defective mitochondrial biogenesis, defective autophagy, mitophagy and synaptic dysfunction in APP transgenic mouse model of Alzheimer's disease (ad). We treated 12-month-old wild-type (WT) and age-matched transgenic APP mice with citalopram for 2 months. Using Morris Water Maze and rotarod tests, quantitative RT-PCR, immunoblotting, biochemical methods and transmission electron microscopy methods, we assessed cognitive behavior, RNA and protein levels of mitochondrial dynamics, biogenesis, autophagy, mitophagy, synaptic, ad-related and neurogenesis genes in wild-type and APP mice treated and untreated with citalopram. Citalopram-treated APP mice relative to citalopram-untreated APP mice exhibited improved cognitive behavior. Increased levels of mRNA associated with mitochondrial fission and ad-related genes; decreased levels of fusion, biogenesis, autophagy, mitophagy, synaptic and neurogenesis genes were found in APP mice relative to WT mice. However, APP mice treated with citalopram compared to citalopram-untreated APP mice revealed reduced levels of the mitochondrial fission and ad-related genes and increased fusion, biogenesis, autophagy, mitophagy, synaptic and neurogenesis genes. Our protein data agree with the mRNA levels. Transmission electron microscopy revealed significantly increased mitochondrial numbers and reduced mitochondrial length in APP mice; these were reversed in citalopram-treated APP mice. Further, Golgi-cox staining analysis revealed reduced dendritic spines in APP mice relative to WT mice. However, citalopram-treated APP mice showed significantly increased dendritic spines, indicating that citalopram enhances spine density, synaptic activity and improved cognitive function in APP mice. These findings suggest that citalopram reduces cognitive decline, Aβ levels and mitochondrial and synaptic toxicities and may have a strong protective role against mutant APP and Aβ-induced injuries in patients with depression, anxiety and ad.

Citing Articles

Modulating Amyloid-β Toxicity: In Vitro Analysis of Aβ42(G37V) Variant Impact on Aβ42 Aggregation and Cytotoxicity.

Huang S, Fang S, Yang C, Liou J, Chen Y Int J Mol Sci. 2024; 25(23).

PMID: 39684928 PMC: 11642391. DOI: 10.3390/ijms252313219.


Caveolae with serotonin and NMDA receptors as promising targets for the treatment of Alzheimer's disease.

Nakashima M, Suga N, Fukumoto A, Yoshikawa S, Matsuda S Int J Physiol Pathophysiol Pharmacol. 2024; 16(5):96-110.

PMID: 39583750 PMC: 11579522. DOI: 10.62347/MTWV3745.


Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?.

Zhang S, Lu J, Jin Z, Xu H, Zhang D, Chen J Front Pharmacol. 2024; 15:1459655.

PMID: 39355779 PMC: 11442227. DOI: 10.3389/fphar.2024.1459655.


Delirium in nursing home residents: is there a role of antidepressants? A cross sectional study.

Fedecostante M, Balietti P, Di Santo S, Zambon A, Marengoni A, Morandi A BMC Geriatr. 2024; 24(1):767.

PMID: 39289644 PMC: 11409737. DOI: 10.1186/s12877-024-05360-z.


Caveolae with GLP-1 and NMDA Receptors as Crossfire Points for the Innovative Treatment of Cognitive Dysfunction Associated with Neurodegenerative Diseases.

Nakashima M, Suga N, Yoshikawa S, Matsuda S Molecules. 2024; 29(16).

PMID: 39203005 PMC: 11357136. DOI: 10.3390/molecules29163922.


References
1.
Reddy P, Tripathi R, Troung Q, Tirumala K, Reddy T, Anekonda V . Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta. 2011; 1822(5):639-49. PMC: 3272314. DOI: 10.1016/j.bbadis.2011.10.011. View

2.
Reddy P, Manczak M, Yin X, Grady M, Mitchell A, Kandimalla R . Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease. J Investig Med. 2016; 64(8):1220-1234. PMC: 5256118. DOI: 10.1136/jim-2016-000240. View

3.
John A, Reddy P . Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res Rev. 2020; 65:101208. PMC: 7770124. DOI: 10.1016/j.arr.2020.101208. View

4.
Grontvedt G, Navarro Schroder T, Sando S, White L, Brathen G, Doeller C . Alzheimer's disease. Curr Biol. 2018; 28(11):R645-R649. DOI: 10.1016/j.cub.2018.04.080. View

5.
Volloch V, Olsen B, Rits S . Alzheimer's Disease Prevention and Treatment: Case for Optimism. Ann Integr Mol Med. 2020; 2(1):115-130. PMC: 7546530. DOI: 10.33597/aimm.02-1008. View